The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic.
Identifieur interne : 000150 ( Main/Exploration ); précédent : 000149; suivant : 000151The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic.
Auteurs : Benjamas Chuaychoo [Thaïlande] ; Uraiwan Kositanont [Thaïlande] ; Nuttapol Rittayamai [Thaïlande] ; Parichat Niyomthong [Thaïlande] ; Thaweesak Songserm [Thaïlande] ; Khun Nanta Maranetra [Thaïlande] ; Kanokwan Rattanasaengloet [Thaïlande] ; Arth Nana [Thaïlande]Source :
- Human vaccines & immunotherapeutics [ 2164-554X ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen (MeSH), Anticorps antiviraux (sang), Broncho-pneumopathie chronique obstructive (complications), Femelle (MeSH), France (MeSH), Grippe humaine (prévention et contrôle), Humains (MeSH), Injections intradermiques (MeSH), Injections musculaires (MeSH), Mâle (MeSH), Sous-type H1N1 du virus de la grippe A (immunologie), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (immunologie), Études prospectives (MeSH).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- immunologie : Sous-type H1N1 du virus de la grippe A, Vaccins antigrippaux.
- prévention et contrôle : Grippe humaine.
- sang : Anticorps antiviraux, Broncho-pneumopathie chronique obstructive.
- Adulte d'âge moyen, Femelle, France, Humains, Injections intradermiques, Injections musculaires, Mâle, Sujet âgé, Sujet âgé de 80 ans ou plus, Études prospectives.
English descriptors
- KwdEn :
- Aged (MeSH), Aged, 80 and over (MeSH), Antibodies, Viral (blood), Female (MeSH), France (MeSH), Humans (MeSH), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (immunology), Influenza, Human (prevention & control), Injections, Intradermal (MeSH), Injections, Intramuscular (MeSH), Male (MeSH), Middle Aged (MeSH), Prospective Studies (MeSH), Pulmonary Disease, Chronic Obstructive (complications).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , blood : Antibodies, Viral.
- complications : Pulmonary Disease, Chronic Obstructive.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza Vaccines.
- prevention & control : Influenza, Human.
- Aged, Aged, 80 and over, Female, France, Humans, Injections, Intradermal, Injections, Intramuscular, Male, Middle Aged, Prospective Studies.
Abstract
The antibody responses of a reduced-dose intradermal seasonal influenza vaccination have never been studied in COPD patients soon after a pandemic. A total of 149 COPD patients (60 y of age or older) were randomized to receive trivalent influenza vaccine (Sanofi-Pasteur, France) either 9 µg of hemagglutinin (HA) per strain split into 2-site intradermal (ID) injections via the Mantoux technique or one intramuscular (IM) injection of 15 µg of HA per strain. The geometric mean titers, seroconversion factors, seroconversion rates and seroprotection rates for influenza A(H3N2) and B administered through the ID injection (n = 75) were similar to those obtained with the IM injection (n = 74) 4 weeks post-vaccination. The antibody responses for influenza A(H1N1)pdm09 administered through the ID injection were lower than those obtained with the IM injection, but all of these responses met the 3 criteria proposed by the Committee for Proprietary Medicinal Products (CPMP) for annual re-licensure. The seroprotection rates 4 weeks post-vaccination for influenza A(H1N1)pdm09 were 64.0% (95%CI 52.7-74.0%) in the ID group vs. 78.4% (95% CI 67.6-86.3%) in the IM group (p = 0.053). Influenza-related acute respiratory illness (ARI), diagnosed as a 4-fold rise in HI titers with a convalescent titer > 1:40, and/or the RT-PCR between the ID group (5.3%) and the IM group (8.1%) were not significantly different. The reduced-dose intradermal influenza vaccine may expand vaccine coverage in cases of vaccine shortage.
DOI: 10.1080/21645515.2016.1149276
PubMed: 27153158
PubMed Central: PMC4964808
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic.</title><author><name sortKey="Chuaychoo, Benjamas" sort="Chuaychoo, Benjamas" uniqKey="Chuaychoo B" first="Benjamas" last="Chuaychoo">Benjamas Chuaychoo</name><affiliation wicri:level="1"><nlm:affiliation>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok </wicri:regionArea><wicri:noRegion>Bangkok </wicri:noRegion></affiliation></author><author><name sortKey="Kositanont, Uraiwan" sort="Kositanont, Uraiwan" uniqKey="Kositanont U" first="Uraiwan" last="Kositanont">Uraiwan Kositanont</name><affiliation wicri:level="1"><nlm:affiliation>b Department of Microbiology ; Siriraj Hospital , Bangkok , Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>b Department of Microbiology ; Siriraj Hospital , Bangkok </wicri:regionArea><wicri:noRegion>Bangkok </wicri:noRegion></affiliation></author><author><name sortKey="Rittayamai, Nuttapol" sort="Rittayamai, Nuttapol" uniqKey="Rittayamai N" first="Nuttapol" last="Rittayamai">Nuttapol Rittayamai</name><affiliation wicri:level="1"><nlm:affiliation>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok </wicri:regionArea><wicri:noRegion>Bangkok </wicri:noRegion></affiliation></author><author><name sortKey="Niyomthong, Parichat" sort="Niyomthong, Parichat" uniqKey="Niyomthong P" first="Parichat" last="Niyomthong">Parichat Niyomthong</name><affiliation wicri:level="1"><nlm:affiliation>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok </wicri:regionArea><wicri:noRegion>Bangkok </wicri:noRegion></affiliation></author><author><name sortKey="Songserm, Thaweesak" sort="Songserm, Thaweesak" uniqKey="Songserm T" first="Thaweesak" last="Songserm">Thaweesak Songserm</name><affiliation wicri:level="1"><nlm:affiliation>c Department of Veterinary Pathology , KamphaengSaen , Nakhon Pathom , Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>c Department of Veterinary Pathology , KamphaengSaen , Nakhon Pathom </wicri:regionArea><wicri:noRegion>Nakhon Pathom </wicri:noRegion></affiliation></author><author><name sortKey="Maranetra, Khun Nanta" sort="Maranetra, Khun Nanta" uniqKey="Maranetra K" first="Khun Nanta" last="Maranetra">Khun Nanta Maranetra</name><affiliation wicri:level="1"><nlm:affiliation>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok </wicri:regionArea><wicri:noRegion>Bangkok </wicri:noRegion></affiliation></author><author><name sortKey="Rattanasaengloet, Kanokwan" sort="Rattanasaengloet, Kanokwan" uniqKey="Rattanasaengloet K" first="Kanokwan" last="Rattanasaengloet">Kanokwan Rattanasaengloet</name><affiliation wicri:level="1"><nlm:affiliation>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok </wicri:regionArea><wicri:noRegion>Bangkok </wicri:noRegion></affiliation></author><author><name sortKey="Nana, Arth" sort="Nana, Arth" uniqKey="Nana A" first="Arth" last="Nana">Arth Nana</name><affiliation wicri:level="1"><nlm:affiliation>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok </wicri:regionArea><wicri:noRegion>Bangkok </wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27153158</idno><idno type="pmid">27153158</idno><idno type="doi">10.1080/21645515.2016.1149276</idno><idno type="pmc">PMC4964808</idno><idno type="wicri:Area/Main/Corpus">000160</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000160</idno><idno type="wicri:Area/Main/Curation">000160</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000160</idno><idno type="wicri:Area/Main/Exploration">000160</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic.</title><author><name sortKey="Chuaychoo, Benjamas" sort="Chuaychoo, Benjamas" uniqKey="Chuaychoo B" first="Benjamas" last="Chuaychoo">Benjamas Chuaychoo</name><affiliation wicri:level="1"><nlm:affiliation>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok </wicri:regionArea><wicri:noRegion>Bangkok </wicri:noRegion></affiliation></author><author><name sortKey="Kositanont, Uraiwan" sort="Kositanont, Uraiwan" uniqKey="Kositanont U" first="Uraiwan" last="Kositanont">Uraiwan Kositanont</name><affiliation wicri:level="1"><nlm:affiliation>b Department of Microbiology ; Siriraj Hospital , Bangkok , Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>b Department of Microbiology ; Siriraj Hospital , Bangkok </wicri:regionArea><wicri:noRegion>Bangkok </wicri:noRegion></affiliation></author><author><name sortKey="Rittayamai, Nuttapol" sort="Rittayamai, Nuttapol" uniqKey="Rittayamai N" first="Nuttapol" last="Rittayamai">Nuttapol Rittayamai</name><affiliation wicri:level="1"><nlm:affiliation>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok </wicri:regionArea><wicri:noRegion>Bangkok </wicri:noRegion></affiliation></author><author><name sortKey="Niyomthong, Parichat" sort="Niyomthong, Parichat" uniqKey="Niyomthong P" first="Parichat" last="Niyomthong">Parichat Niyomthong</name><affiliation wicri:level="1"><nlm:affiliation>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok </wicri:regionArea><wicri:noRegion>Bangkok </wicri:noRegion></affiliation></author><author><name sortKey="Songserm, Thaweesak" sort="Songserm, Thaweesak" uniqKey="Songserm T" first="Thaweesak" last="Songserm">Thaweesak Songserm</name><affiliation wicri:level="1"><nlm:affiliation>c Department of Veterinary Pathology , KamphaengSaen , Nakhon Pathom , Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>c Department of Veterinary Pathology , KamphaengSaen , Nakhon Pathom </wicri:regionArea><wicri:noRegion>Nakhon Pathom </wicri:noRegion></affiliation></author><author><name sortKey="Maranetra, Khun Nanta" sort="Maranetra, Khun Nanta" uniqKey="Maranetra K" first="Khun Nanta" last="Maranetra">Khun Nanta Maranetra</name><affiliation wicri:level="1"><nlm:affiliation>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok </wicri:regionArea><wicri:noRegion>Bangkok </wicri:noRegion></affiliation></author><author><name sortKey="Rattanasaengloet, Kanokwan" sort="Rattanasaengloet, Kanokwan" uniqKey="Rattanasaengloet K" first="Kanokwan" last="Rattanasaengloet">Kanokwan Rattanasaengloet</name><affiliation wicri:level="1"><nlm:affiliation>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok </wicri:regionArea><wicri:noRegion>Bangkok </wicri:noRegion></affiliation></author><author><name sortKey="Nana, Arth" sort="Nana, Arth" uniqKey="Nana A" first="Arth" last="Nana">Arth Nana</name><affiliation wicri:level="1"><nlm:affiliation>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok </wicri:regionArea><wicri:noRegion>Bangkok </wicri:noRegion></affiliation></author></analytic><series><title level="j">Human vaccines & immunotherapeutics</title><idno type="eISSN">2164-554X</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Antibodies, Viral (blood)</term><term>Female (MeSH)</term><term>France (MeSH)</term><term>Humans (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Injections, Intradermal (MeSH)</term><term>Injections, Intramuscular (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Prospective Studies (MeSH)</term><term>Pulmonary Disease, Chronic Obstructive (complications)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term><term>Anticorps antiviraux (sang)</term><term>Broncho-pneumopathie chronique obstructive (complications)</term><term>Femelle (MeSH)</term><term>France (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Humains (MeSH)</term><term>Injections intradermiques (MeSH)</term><term>Injections musculaires (MeSH)</term><term>Mâle (MeSH)</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (immunologie)</term><term>Études prospectives (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Pulmonary Disease, Chronic Obstructive</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Broncho-pneumopathie chronique obstructive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>France</term><term>Humans</term><term>Injections, Intradermal</term><term>Injections, Intramuscular</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term><term>Femelle</term><term>France</term><term>Humains</term><term>Injections intradermiques</term><term>Injections musculaires</term><term>Mâle</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études prospectives</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The antibody responses of a reduced-dose intradermal seasonal influenza vaccination have never been studied in COPD patients soon after a pandemic. A total of 149 COPD patients (60 y of age or older) were randomized to receive trivalent influenza vaccine (Sanofi-Pasteur, France) either 9 µg of hemagglutinin (HA) per strain split into 2-site intradermal (ID) injections via the Mantoux technique or one intramuscular (IM) injection of 15 µg of HA per strain. The geometric mean titers, seroconversion factors, seroconversion rates and seroprotection rates for influenza A(H3N2) and B administered through the ID injection (n = 75) were similar to those obtained with the IM injection (n = 74) 4 weeks post-vaccination. The antibody responses for influenza A(H1N1)pdm09 administered through the ID injection were lower than those obtained with the IM injection, but all of these responses met the 3 criteria proposed by the Committee for Proprietary Medicinal Products (CPMP) for annual re-licensure. The seroprotection rates 4 weeks post-vaccination for influenza A(H1N1)pdm09 were 64.0% (95%CI 52.7-74.0%) in the ID group vs. 78.4% (95% CI 67.6-86.3%) in the IM group (p = 0.053). Influenza-related acute respiratory illness (ARI), diagnosed as a 4-fold rise in HI titers with a convalescent titer > 1:40, and/or the RT-PCR between the ID group (5.3%) and the IM group (8.1%) were not significantly different. The reduced-dose intradermal influenza vaccine may expand vaccine coverage in cases of vaccine shortage.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27153158</PMID><DateCompleted><Year>2017</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>7</Issue><PubDate><Year>2016</Year><Month>07</Month><Day>02</Day></PubDate></JournalIssue><Title>Human vaccines & immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic.</ArticleTitle><Pagination><MedlinePgn>1728-37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2016.1149276</ELocationID><Abstract><AbstractText>The antibody responses of a reduced-dose intradermal seasonal influenza vaccination have never been studied in COPD patients soon after a pandemic. A total of 149 COPD patients (60 y of age or older) were randomized to receive trivalent influenza vaccine (Sanofi-Pasteur, France) either 9 µg of hemagglutinin (HA) per strain split into 2-site intradermal (ID) injections via the Mantoux technique or one intramuscular (IM) injection of 15 µg of HA per strain. The geometric mean titers, seroconversion factors, seroconversion rates and seroprotection rates for influenza A(H3N2) and B administered through the ID injection (n = 75) were similar to those obtained with the IM injection (n = 74) 4 weeks post-vaccination. The antibody responses for influenza A(H1N1)pdm09 administered through the ID injection were lower than those obtained with the IM injection, but all of these responses met the 3 criteria proposed by the Committee for Proprietary Medicinal Products (CPMP) for annual re-licensure. The seroprotection rates 4 weeks post-vaccination for influenza A(H1N1)pdm09 were 64.0% (95%CI 52.7-74.0%) in the ID group vs. 78.4% (95% CI 67.6-86.3%) in the IM group (p = 0.053). Influenza-related acute respiratory illness (ARI), diagnosed as a 4-fold rise in HI titers with a convalescent titer > 1:40, and/or the RT-PCR between the ID group (5.3%) and the IM group (8.1%) were not significantly different. The reduced-dose intradermal influenza vaccine may expand vaccine coverage in cases of vaccine shortage.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chuaychoo</LastName><ForeName>Benjamas</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kositanont</LastName><ForeName>Uraiwan</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>b Department of Microbiology ; Siriraj Hospital , Bangkok , Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rittayamai</LastName><ForeName>Nuttapol</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niyomthong</LastName><ForeName>Parichat</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Songserm</LastName><ForeName>Thaweesak</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>c Department of Veterinary Pathology , KamphaengSaen , Nakhon Pathom , Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maranetra</LastName><ForeName>Khun Nanta</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rattanasaengloet</LastName><ForeName>Kanokwan</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nana</LastName><ForeName>Arth</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>a Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital , Bangkok , Thailand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007271" MajorTopicYN="N">Injections, Intradermal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007273" MajorTopicYN="N">Injections, Intramuscular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029424" MajorTopicYN="N">Pulmonary Disease, Chronic Obstructive</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COPD</Keyword><Keyword MajorTopicYN="Y">acute respiratory illness</Keyword><Keyword MajorTopicYN="Y">immunogenicity</Keyword><Keyword MajorTopicYN="Y">influenza A(H1N1)pdm09</Keyword><Keyword MajorTopicYN="Y">influenza vaccine</Keyword><Keyword MajorTopicYN="Y">intradermal</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>10</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27153158</ArticleId><ArticleId IdType="doi">10.1080/21645515.2016.1149276</ArticleId><ArticleId IdType="pmc">PMC4964808</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Vaccine. 2008 Dec 2;26(51):6614-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18930093</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2009 Apr 02;7:13</Citation><ArticleIdList><ArticleId IdType="pubmed">19341446</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dev Ctries. 2013 Oct 15;7(10):734-40</Citation><ArticleIdList><ArticleId IdType="pubmed">24129626</ArticleId></ArticleIdList></Reference><Reference><Citation>J Health Popul Nutr. 2010 Dec;28(6):537-44</Citation><ArticleIdList><ArticleId IdType="pubmed">21261198</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2004 Nov 25;351(22):2295-301</Citation><ArticleIdList><ArticleId IdType="pubmed">15525714</ArticleId></ArticleIdList></Reference><Reference><Citation>Br Med J. 1966 Sep 17;2(5515):671-3</Citation><ArticleIdList><ArticleId IdType="pubmed">20791109</ArticleId></ArticleIdList></Reference><Reference><Citation>Viral Immunol. 2012 Dec;25(6):471-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23061793</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2004 Jun;125(6):2011-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15189916</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2013 May 1;31(19):2358-65</Citation><ArticleIdList><ArticleId IdType="pubmed">23499604</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 2006 Jan;129(1 Suppl):1S-23S</Citation><ArticleIdList><ArticleId IdType="pubmed">16428686</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2010 May 15;50(10):1331-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20377407</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2004 Nov 25;351(22):2286-94</Citation><ArticleIdList><ArticleId IdType="pubmed">15525713</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Sep 17;25(37-38):6755-63</Citation><ArticleIdList><ArticleId IdType="pubmed">17692438</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Ther. 2011 Jul;28(7):555-65</Citation><ArticleIdList><ArticleId IdType="pubmed">21626269</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Oct 5;30(45):6427-35</Citation><ArticleIdList><ArticleId IdType="pubmed">22910287</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Assoc Thai. 2004 Aug;87(8):964-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15471303</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1987 Feb;106(2):196-204</Citation><ArticleIdList><ArticleId IdType="pubmed">3492164</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Assoc Thai. 2005 Feb;88(2):256-64</Citation><ArticleIdList><ArticleId IdType="pubmed">15962680</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2009 Dec 9;27(52):7304-12</Citation><ArticleIdList><ArticleId IdType="pubmed">19849996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2004 Jan 10;363(9403):157-63</Citation><ArticleIdList><ArticleId IdType="pubmed">14726171</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Infect Control. 2011 Aug;39(6):525-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21612842</ArticleId></ArticleIdList></Reference><Reference><Citation>Viral Immunol. 2010 Jun;23(3):329-34</Citation><ArticleIdList><ArticleId IdType="pubmed">20565296</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Crit Care Med. 2007 Sep 15;176(6):532-55</Citation><ArticleIdList><ArticleId IdType="pubmed">17507545</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 May 28;28(24):4045-51</Citation><ArticleIdList><ArticleId IdType="pubmed">20412877</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2007 Jan 8;25(4):659-63</Citation><ArticleIdList><ArticleId IdType="pubmed">17011678</ArticleId></ArticleIdList></Reference><Reference><Citation>Chest. 1994 Nov;106(5):1463-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7956403</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Thaïlande</li></country></list><tree><country name="Thaïlande"><noRegion><name sortKey="Chuaychoo, Benjamas" sort="Chuaychoo, Benjamas" uniqKey="Chuaychoo B" first="Benjamas" last="Chuaychoo">Benjamas Chuaychoo</name></noRegion><name sortKey="Kositanont, Uraiwan" sort="Kositanont, Uraiwan" uniqKey="Kositanont U" first="Uraiwan" last="Kositanont">Uraiwan Kositanont</name><name sortKey="Maranetra, Khun Nanta" sort="Maranetra, Khun Nanta" uniqKey="Maranetra K" first="Khun Nanta" last="Maranetra">Khun Nanta Maranetra</name><name sortKey="Nana, Arth" sort="Nana, Arth" uniqKey="Nana A" first="Arth" last="Nana">Arth Nana</name><name sortKey="Niyomthong, Parichat" sort="Niyomthong, Parichat" uniqKey="Niyomthong P" first="Parichat" last="Niyomthong">Parichat Niyomthong</name><name sortKey="Rattanasaengloet, Kanokwan" sort="Rattanasaengloet, Kanokwan" uniqKey="Rattanasaengloet K" first="Kanokwan" last="Rattanasaengloet">Kanokwan Rattanasaengloet</name><name sortKey="Rittayamai, Nuttapol" sort="Rittayamai, Nuttapol" uniqKey="Rittayamai N" first="Nuttapol" last="Rittayamai">Nuttapol Rittayamai</name><name sortKey="Songserm, Thaweesak" sort="Songserm, Thaweesak" uniqKey="Songserm T" first="Thaweesak" last="Songserm">Thaweesak Songserm</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000150 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000150 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27153158
|texte= The immunogenicity of the intradermal injection of seasonal trivalent influenza vaccine containing influenza A(H1N1)pdm09 in COPD patients soon after a pandemic.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27153158" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeFranceV1
| This area was generated with Dilib version V0.6.35. |  |